0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The impact of structural biology in medicine illustrated with four case studies.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The contributions of structural biology to drug discovery have expanded over the last 20 years from structure-based ligand optimization to a broad range of clinically relevant topics including the understanding of disease, target discovery, screening for new types of ligands, discovery of new modes of action, addressing clinical challenges such as side effects or resistance, and providing data to support drug registration. This expansion of scope is due to breakthroughs in the technology, which allow structural information to be obtained rapidly and for more complex molecular systems, but also due to the combination of different technologies such as X-ray, NMR, and other biophysical methods, which allows one to get a more complete molecular understanding of disease and ways to treat it. In this review, we provide examples of the types of impact molecular structure information can have in the clinic for both low molecular weight and biologic drug discovery and describe several case studies from our own work to illustrate some of these contributions.

          Related collections

          Author and article information

          Journal
          J Mol Med (Berl)
          Journal of molecular medicine (Berlin, Germany)
          Springer Science and Business Media LLC
          1432-1440
          0946-2716
          January 2018
          : 96
          : 1
          Affiliations
          [1 ] Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA.
          [2 ] Novartis Institutes for Biomedical Research, 4002, Basel, Switzerland. Sandra.jacob@novartis.com.
          Article
          10.1007/s00109-017-1565-x
          10.1007/s00109-017-1565-x
          28669027
          95f75667-00f1-4b01-9145-0295a9c96981
          History

          Structural biology,Conformation,Drug discovery,Allosteric,Inhibitors

          Comments

          Comment on this article